IPAB sets aside Sutent patent rejection
07-06-2013
India’s Patent Office has revoked pharmaceutical company Sugen and licensee Pfizer’s patent for the cancer drug Sutent, agreeing with Indian drugs maker Cipla that it lacks inventive step.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com
India, Patent Office, Pfizer, Sugen, Sutent, Cipla
